Clinical Trials In Irvine

Discover hundreds of clinical trials in Irvine.
Search clinical trials in Irvine by condition or phase.

e.g. Respiratory Diseases

Irvine•Healthy volunteers: No

Filter results

Results: 3,428

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Recruiting

Phase 1

Sponsor:

Ono Pharmaceutical Co. Ltd

Location:

Orange, Duarte, Birmingham, Bostonshow 7 more

Code:

NCT05079282

Conditions

Relapsed or Refractory T Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ONO-4685

Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)

Recruiting

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

San Francisco, Palo Alto, Los Angeles, New Havenshow 6 more

Code:

NCT01196182

Conditions

Congenital Heart Defects

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Flashed Light Therapy for Adolescents With ADHD and Delayed Sleep Timing

Recruiting

Sponsor:

UCLA

Location:

Los Angeles

Code:

NCT06036420

Conditions

ADHD

Eligibility Criteria

Sex: All

Age: 14 - 17

Healthy Volunteers: Not accepted

Interventions

Flashed Light Therapy

Videoconference-delivered Cognitive Behavioral Therapy

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

Sponsor:

Qurient Co., Ltd.

Location:

Los Angeles, Louisville

Code:

NCT05438420

Conditions

Esophageal Cancer

Gastric Cancer

Hepatocellular Cancer

Cervical Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Q702

Pembrolizumab

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis

Recruiting

Sponsor:

NIH

Location:

Los Angeles, Minneapolis, Salt Lake City

Code:

NCT01543620

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Recruiting

Phase 2

Sponsor:

CARGO Therapeutics

Location:

Stanford, Los Angeles, Duarte, Little Rockshow 23 more

Code:

NCT05972720

Conditions

Cancer

Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fludarabine (Conditional therapy)

Cyclophosphamide Monohydrate (Conditional therapy)

firi-cel (Experimental drug)

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Recruiting

Phase 2

Sponsor:

Evommune, Inc.

Location:

San Diego, Los Angeles, Birmingham, Tampashow 11 more

Code:

NCT06603220

Conditions

Chronic Inducible Urticaria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Oral EVO756

BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours

Recruiting

Phase 1

Phase 2

Sponsor:

Bold Therapeutics, Inc.

Location:

Santa Monica, Tampa

Code:

NCT04421820

Conditions

Colorectal Cancer

Pancreatic Cancer

Gastric Cancers

Cholangiocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting

Phase 1

Phase 2

Sponsor:

Stemline Therapeutics, Inc.

Location:

Whittier, San Francisco, Los Angeles, Los Alamitosshow 37 more

Code:

NCT05563220

Conditions

Breast Cancer

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elacestrant

Alpelisib

Everolimus

Ribociclib

Palbociclib

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

Phase 3

Sponsor:

Novartis Pharmaceuticals

Location:

Pomona, Pasadena, Newport Beach, Glendaleshow 60 more

Code:

NCT05147220

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

e.g. Respiratory Diseases

Irvine•Healthy volunteers: No

Filter results

Results: 3,428

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Recruiting

Phase 1

Sponsor:

Ono Pharmaceutical Co. Ltd

Location:

Orange, Duarte, Birmingham, Bostonshow 7 more

Code:

NCT05079282

Conditions

Relapsed or Refractory T Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ONO-4685

Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)

Recruiting

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

San Francisco, Palo Alto, Los Angeles, New Havenshow 6 more

Code:

NCT01196182

Conditions

Congenital Heart Defects

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Flashed Light Therapy for Adolescents With ADHD and Delayed Sleep Timing

Recruiting

Sponsor:

UCLA

Location:

Los Angeles

Code:

NCT06036420

Conditions

ADHD

Eligibility Criteria

Sex: All

Age: 14 - 17

Healthy Volunteers: Not accepted

Interventions

Flashed Light Therapy

Videoconference-delivered Cognitive Behavioral Therapy

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

Sponsor:

Qurient Co., Ltd.

Location:

Los Angeles, Louisville

Code:

NCT05438420

Conditions

Esophageal Cancer

Gastric Cancer

Hepatocellular Cancer

Cervical Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Q702

Pembrolizumab

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis

Recruiting

Sponsor:

NIH

Location:

Los Angeles, Minneapolis, Salt Lake City

Code:

NCT01543620

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Recruiting

Phase 2

Sponsor:

CARGO Therapeutics

Location:

Stanford, Los Angeles, Duarte, Little Rockshow 23 more

Code:

NCT05972720

Conditions

Cancer

Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fludarabine (Conditional therapy)

Cyclophosphamide Monohydrate (Conditional therapy)

firi-cel (Experimental drug)

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Recruiting

Phase 2

Sponsor:

Evommune, Inc.

Location:

San Diego, Los Angeles, Birmingham, Tampashow 11 more

Code:

NCT06603220

Conditions

Chronic Inducible Urticaria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Oral EVO756

BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours

Recruiting

Phase 1

Phase 2

Sponsor:

Bold Therapeutics, Inc.

Location:

Santa Monica, Tampa

Code:

NCT04421820

Conditions

Colorectal Cancer

Pancreatic Cancer

Gastric Cancers

Cholangiocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting

Phase 1

Phase 2

Sponsor:

Stemline Therapeutics, Inc.

Location:

Whittier, San Francisco, Los Angeles, Los Alamitosshow 37 more

Code:

NCT05563220

Conditions

Breast Cancer

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elacestrant

Alpelisib

Everolimus

Ribociclib

Palbociclib

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

Phase 3

Sponsor:

Novartis Pharmaceuticals

Location:

Pomona, Pasadena, Newport Beach, Glendaleshow 60 more

Code:

NCT05147220

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide